They observed that SS patients with an HLA-A*02 genotype had a shorter OS when survival was analyzed from the time of metastasis, indicating this genotype as a negative prognostic factor and that HLA genotype is a relevant predictive biomarker for SS patients interested in receiving genetically engineered T cells (60). This evidence concerns the gene HLA-A and synovial sarcoma.